GRAIL, Inc.: Business Overview, Financials & Competitive Analysis
GRAIL, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Early-stage cancer detection innovator with transformative potential, but clinical validation setbacks and path to profitability create elevated execution risk. GRAIL shows strong clinical positioning and analyst support (Strong Buy consensus), with improving financial trajectory and 110% stock performance over past year. However, recent NHS-Galleri trial failure in February 2026 to.
What is GRAIL, Inc.'s industry? GRAIL, Inc. (grail.com) operates in Diagnostics & Cancer Detection - Multi-Cancer Early Detection (MCED). AskCyborg classifies GRAIL, Inc. under Diagnostics & Cancer Detection - Multi-Cancer Early Detection (MCED) in its company registry.
GRAIL is a commercial-stage healthcare company developing Galleri, a blood-based multi-cancer early detection test for asymptomatic individuals over 50. The company's mission is to detect cancer early when it can be c...
Cyborg Score thesis
Early-stage cancer detection innovator with transformative potential, but clinical validation setbacks and path to profitability...
Read the full analyst-debate transcript →Get the Latest GRAIL, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeGRAIL, Inc. Overview
Pro stress-test →GRAIL is a commercial-stage healthcare company developing Galleri, a blood-based multi-cancer early detection test for asymptomatic individuals over 50. The company's mission is to detect cancer early when it can be cured, utilizing next-generation sequencing and machine learning to identify multiple cancer types in earlier stages.
Strategic Profile
Pro stress-test →GRAIL leverages a targeted methylation-based platform supporting the continuum of care from screening to precision oncology, including minimal residual disease detection and treatment monitoring. The company is positioned as a leader in multi-cancer early detection (MCED), with revenue growing 17% to $147.2M in 2025, though it remains unprofitable as it scales commercial adoption.
Competitive Landscape
Pro stress-test →GRAIL operates in the emerging MCED space with competitors including Guardant Health (Shield multi-cancer screening), Tempus (precision oncology platform), and Foundation Medicine (oncology diagnostics). GRAIL's differentiation lies in its targeted methylation platform and clinical validation through population-scale studies, though recent trial failures have shifted competitive dynamics.
Industry Context
GRAIL, Inc. operates in Diagnostics & Cancer Detection - Multi-Cancer Early Detection (MCED).
Key facts
Founded: 2015 · Headquarters: Menlo Park, California · Revenue: $147.2M · Market cap: $5.3B